lifestyle.capitolhilltimes.com

Author: HOTH THERAPEUTICS, INC.

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

February 24, 2026
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

February 12, 2026
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth’s HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

February 12, 2026
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

February 11, 2026
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

January 23, 2026
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

January 21, 2026
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

January 15, 2026
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

January 2, 2026
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

December 4, 2025
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

December 1, 2025